<DOC>
	<DOC>NCT01956513</DOC>
	<brief_summary>The main objective of the study is to assess the sensitivity and the specificity of the variation of apparent diffusion coefficient for prediction, after a course of neoadjuvant chemotherapy or after modification of the treatment sequence, the pathological response at the end of chemotherapy</brief_summary>
	<brief_title>Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer</brief_title>
	<detailed_description />
	<criteria>Age&gt; 18 years. Patient suffering from a breast tumor, regardless of the stage and size Patient requiring neoadjuvant chemotherapy Patient has the ability to undergo 18FFDGPET at baseline, at end of cycle 1 and at the end of neoadjuvant treatment before surgery Compulsory affiliation to a social security system. Obtaining informed consent in writing, signed and dated. Patient with cognitive or psychiatric disorders. Patient deprived of liberty by a court or administrative. Patient with signs against the achievement of MRI, mammography and ultrasound Patient metastatic Patient with prior chemotherapy, radiotherapy and hormone therapy for her breast cancer Pregnant women, current lactation Patient suffering from uncontrolled diabetes (&gt; 11 mmol / L)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>ADC</keyword>
	<keyword>breast cancer</keyword>
	<keyword>complete pathological response</keyword>
</DOC>